InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (10 ops.)
Discover the detailed record of transactions filed by THOMAS LAMY, Vice-Président et cofondateur de BIOSYNEX. Insider active across 1 companies, notably BIOSYNEX. Cumulatively, 14 disclosures have been logged. Total volume traded: €3.5m. The latest transaction was disclosed on 28 January 2025 (Cession). Regulator: AMF. The full history is free.
Declarations14 total
€1,682168,184 shares@ €0.010.0094% mcap0.0% of flow
DPSHors plateforme de négociation
2025DD1018147·
€51,4292,975 shares@ €17.2870.29% mcap1.3% of flow
ActionEuronext Growth Paris
2022DD820970·
Ideal exit: 7 Nov 2022 (T+270)
€121,8957,025 shares@ €17.35160.68% mcap3.2% of flow
ActionEuronext Growth Paris
2022DD820971·
Ideal exit: 8 Nov 2022 (T+270)
€74,5752,849 shares@ €26.17570.42% mcap1.9% of flow
ActionEuronext Growth Paris
2021DD746925·
€251,7579,664 shares@ €26.0511.40% mcap6.6% of flow
ActionEuronext Growth Paris
2021DD746015·
€68,9252,637 shares@ €26.13760.38% mcap1.8% of flow
ActionEuronext Growth Paris
2021DD746014·
€46,3451,780 shares@ €26.03630.26% mcap1.2% of flow
ActionEuronext Growth Paris
2021DD746013·
€9,992383 shares@ €26.08770.056% mcap0.3% of flow
ActionEuronext Growth Paris
2021DD744200·
€636,69524,215 shares@ €26.29343.54% mcap16.6% of flow
ActionEuronext Growth Paris
2021DD744196·
€837,65231,895 shares@ €26.26284.66% mcap21.9% of flow
ActionEuronext Growth Paris
2021DD744194·
€676,91325,785 shares@ €26.25223.77% mcap17.7% of flow
ActionEuronext Growth Paris
2021DD744192·
€677,07925,792 shares@ €26.25153.77% mcap17.7% of flow
ActionEuronext Growth Paris
2021DD744189·
€346,58034,658 shares@ €10.001.93% mcap9.0% of flow
BSARHors plateforme de négociation
2021DD742195·
€31,2403,124 shares@ €10.000.17% mcap0.8% of flow
BSARHors plateforme de négociation
2021DD742011·
14 of 14 declarations
About THOMAS LAMY
Thomas Lamy is a long-standing executive figure at BIOSYNEX, the French in vitro diagnostics and rapid testing group. As a cofounder of the company alongside Larry Abensur and Thierry Paper, he has played a central role in the group’s development and governance over many years. Publicly available sources currently identify him as a director of BIOSYNEX, while the company’s corporate communication stated in May 2024 that he would take the role of Vice-Chairman as part of a governance strengthening initiative. His professional background points to strong commercial and marketing expertise in healthcare and diagnostic-related businesses. His LinkedIn profile shows early experience as a Sales Manager at Johnson & Johnson, followed by sales and marketing responsibilities before his long-term involvement with BIOSYNEX. This path suggests deep familiarity with regulated healthcare markets, product commercialization, and business development. At BIOSYNEX, Lamy helped build and scale a French diagnostics company that operates in rapid diagnostic tests for healthcare professionals, with a footprint in France and abroad. The group gained particular visibility during the COVID-19 period, when its positioning and industrial capacity became more widely recognized. In 2021, the founding trio, including Thomas Lamy, received EY’s regional Entrepreneur of the Year award, underscoring the market recognition of their entrepreneurial track record. His profile also reflects a governance-oriented, founder-shareholder mindset. Recent company filings continue to mention his significant ownership position as a founding shareholder, indicating that his influence extends beyond management into strategic and capital governance. Overall, Thomas Lamy stands out as a healthcare industry executive combining commercial leadership, entrepreneurial continuity, and a lasting contribution to a listed company’s strategic direction.
